Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
James L. Gulley, MD, PhD, chief of the Genitourinary Malignancies Branch, director of Medical Oncology Service, National Cancer Institute, discusses treatment beyond the second line in bladder cancer. Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
Updated Trials at ESMO Reveal New Frontline Combo in Urothelial Carcinoma
December 2nd 2023Findings presented during the 2023 ESMO Annual Meeting have demonstrated a new combination of targeted therapies offering clinicians and patients renewed hope in this difficult to treat cancer type.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More